VPA1 AVEO Pharmaceuticals Inc.

AVEO to Present at the 15th Annual BIO Investor Forum

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 15th Annual BIO Investor Forum on Wednesday, October 19, 2016 at 11:30 AM Pacific Time. The conference is being held at the Westin St. Francis Hotel in San Francisco.

A live webcast can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.

About AVEO

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for Renal Cell Carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome). For more information, please visit the company’s website at www.aveooncology.com.

AVEO Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of AVEO that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Actual results or events could differ materially due to a number of important factors, including risks discussed in the section titled “Risk Factors” in AVEO’s most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its other filings with the SEC. The forward-looking statements in this press release represent AVEO’s views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO’s views as of any date other than the date of this press release.

EN
12/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AVEO Pharmaceuticals Inc.

 PRESS RELEASE

CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Off...

CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee – Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer – – Formation of a Scientific Advisory Committee from world-renowned cancer institutions – BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline on March 25 by AVEO Pharmaceuticals, the text in the second paragraph has been corrected to better reflect Dr. Braendle's clinical research experience. The corrected r...

 PRESS RELEASE

AVEO Oncology Announces Appointment of Chief Medical Officer and Forma...

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee – Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer – – Formation of a Scientific Advisory Committee from world-renowned cancer institutions – BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer. Dr. Braendle is a life sciences executive with ex...

 PRESS RELEASE

AVEO Oncology Announces Publication of Long-Term Survival in Patients ...

AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- , an LG Chem company (“AVEO”), today announced The Oncologist has published a post-hoc analysis of long-term progression free survival, overall survival and safety data from the Phase 3 TIVO-3 trial evaluating FOTIVDA® (tivozanib) in patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC). In the publication, FOTIVDA demo...

 PRESS RELEASE

AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Tria...

AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Phase 3 Registrational Trial Seeks to Improve Survival Outcomes in Underserved HPV-negative R/M Head and Neck Cancer Patient PopulationTrial Launch Follows FDA Fast Track Designation of Ficlatuzumab/cetuximab Combination for Treatment of Relapsed/Recurrent HNSCC BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, t...

 PRESS RELEASE

LG Chem Completes Acquisition of AVEO Oncology

LG Chem Completes Acquisition of AVEO Oncology AVEO to Become the U.S. Foundation for LG Chem Life Sciences’ Oncology Division SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, in an all-cash transaction with an implied equity value of $571M on a fully diluted basis. “We are excited to compl...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch